A phase II/III randomized, double-blind study of paclitaxel plus carboplatin in combination with vorinostat or placebo in patients with stage IIIb (with pleural effusion) or stage IV non-small-cell lung cancer (NSCLC)

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 06 May 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vorinostat (Primary) ; Carboplatin; Paclitaxel
Indications Non-small cell lung cancer
Focus Therapeutic Use
Sponsors Merck & Co; Merck Sharp & Dohme Corp.

Most Recent Events

21 Jun 2019 This trial has been discontinued in Finland.
15 Jun 2019 This trial has been completed in Czech Republic, according to European Clinical Trials Database.
09 Mar 2011 Additional lead trial investigator (Prof David Cameron) identified as reported by United Kingdom Clinical Research Network.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight